Trastuzumab deruxtecan recommended in NICE draft guidance for use in the CDF for breast cancer after two or more anti-HER2 therapies

Treatment will be removed from the CDF on publication of the final guidance if the draft recommendation does not change following public consultation.

OnMedica

Feb 12, 2021

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Oncology, Breast cancer, Oncology Room

#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive disease-free survival in patients with ER⁺ breast cancer

2 Minute Medicine

Feb 10, 2021

SMC accepts leuprorelin acetate for two oncology indications

Regulatory alerts

Cancer, Oncology, Breast cancer, Oncology Room

SMC accepts leuprorelin acetate for two oncology indications

OnMedica

Feb 08, 2021

#VisualAbstract: Fixed-dose, subcutaneous injection of pertuzumab and trastuzumab is non-inferior to intravenous administration in HER2⁺ breast cancer

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Oncology, Breast cancer, Oncology Room

#VisualAbstract: Fixed-dose, subcutaneous injection of pertuzumab and trastuzumab is non-inferior to intravenous administration in HER2⁺ breast cancer

2 Minute Medicine

Feb 03, 2021

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Cancer, Oncology, Breast cancer, Oncology Room

#VisualAbstract: Margetuximab improves progression-free survival in patients with ERBB2⁺ advanced breast cancer compared to trastuzumab

2 Minute Medicine

Jan 28, 2021

#VisualAbstract: Everolimus plus leuprorelin and letrozole improves progression-free survival in HR⁺, HER2⁻ metastatic breast cancer patients with visceral metastases

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Oncology, Breast cancer, Oncology Room

#VisualAbstract: Everolimus plus leuprorelin and letrozole improves progression-free survival in HR⁺, HER2⁻ metastatic breast cancer patients with visceral metastases

2 Minute Medicine

Jan 13, 2021

#VisualAbstract: Low-dose capecitabine after standard adjuvant therapy improves disease-free survival in patients with early triple-negative breast cancer

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Cancer, Breast cancer, Oncology Room

#VisualAbstract: Low-dose capecitabine after standard adjuvant therapy improves disease-free survival in patients with early triple-negative breast cancer

2 Minute Medicine

Jan 08, 2021

#VisualAbstract: Low mammographic breast density may be associated with an increased risk of developing severe lymphedema

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Oncology, Breast cancer, Oncology Room

#VisualAbstract: Low mammographic breast density may be associated with an increased risk of developing severe lymphedema

2 Minute Medicine

Dec 31, 2020

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Breast cancer, Oncology Room

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

2 Minute Medicine

Dec 24, 2020

#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Cancer, Breast cancer, Oncology Room

#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018

2 Minute Medicine

Dec 16, 2020